CJC-1295 Therapy

CJC-1295 works by binding to and activating the growth hormone-releasing hormone receptor (GHRHR) on the anterior pituitary gland, stimulating the pulsatile release of growth hormone. The DAC modification allows the peptide to bind to albumin in the bloodstream, significantly extending its active duration compared to native GHRH. This sustained signaling encourages the liver to produce more insulin-like growth factor 1 (IGF-1), which mediates many of the downstream effects associated with growth hormone. Unlike exogenous growth hormone injection, CJC-1295 works within the body's natural feedback loops, maintaining more physiological patterns of GH release.

CJC-1295 is commonly sought by adults over 30 who are experiencing the natural age-related decline in growth hormone production and wish to support vitality, body composition, and recovery. Athletes and fitness enthusiasts seek it to optimize training recovery and body composition goals. It is also popular among individuals exploring comprehensive anti-aging protocols who prefer a peptide approach over direct growth hormone supplementation.

CJC-1295 is typically administered via subcutaneous injection, most commonly in the abdominal area or thigh. The non-DAC version is often dosed daily, while the DAC version may be administered once or twice per week due to its extended half-life. Evening dosing is frequently recommended to align with the body's natural nighttime growth hormone surge.